STOCK WATCH

DRUG company Indivior has settled a patent row with a US rival that wants to make a knock- off of its heroin substitute.

Indivior – which develops products for recovering addicts – took legal action against Par Pharmaceutical after it sought to develop a generic version of the Suboxone medicine.

The pair have struck a deal which will allow Par to sell its own version in 2023.

The stock fell 0.7pc, or 3.4p, to 457.7p yesterday.